Internal Medicine, Gastroenterology · Jamaica Plain, MA
NPI
1295909661
Since 2008
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
10 Goodrich Rd # 1
Jamaica Plain, MA, 02130
Phone (617) 522-3585
Groups this clinician bills Medicare through
Medicare paid, 2024
$129K
2,816 services
Medicare patients, 2024
450
Average age 73
Drug cost, 2024
$188K
888 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michal F Tomczak was code 45380 (lower gi endoscopy - other), 196 times for 196 patients. In total Michal F Tomczak billed 2,816 services in 74 codes, and Medicare paid $129K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-01-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 45380 Lower GI Endoscopy - Other | Facility | 196 | 196 | $77.21 | $15K |
| 45385 Colonoscopy - Lesion Removal | Facility | 158 | 158 | $202.00 | $32K |
| 99214 Office E&M - Established | Office | 101 | 77 | $100.84 | $10K |
| 43239 Upper GI Endoscopy | Facility | 86 | 85 | $72.35 | $6,222 |
| 36415 Venipuncture Blood Collection | Office | 44 | 37 | $8.65 | $381 |
| 85027 Blood Count | Office | 27 | 23 | $6.34 | $171 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 24 | 24 | $179.93 | $4,318 |
| 99223 Hospital E&M - Initial | Facility | 23 | 23 | $143.94 | $3,311 |
| 99204 Office E&M - New | Office | 23 | 23 | $138.02 | $3,174 |
| 99213 Office E&M - Established | Office | 18 | 17 | $66.55 | $1,198 |
| 82728 Clinical Chemistry | Office | 17 | 14 | $13.36 | $227 |
| 91110 Standard X-ray | Office | 16 | 16 | $639.53 | $10K |
| 83540 Clinical Chemistry | Office | 15 | 12 | $6.34 | $95.1 |
| 84466 Clinical Chemistry | Office | 15 | 12 | $12.50 | $188 |
| 82607 Clinical Chemistry | Office | 14 | 13 | $14.78 | $207 |
By year: 2022 $85K for 856 services; 2023 $90K for 883 services; 2024 $129K for 2,816 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 44 | 37 | $8.65 | $381 |
| 85027 Blood Count | 27 | 23 | $6.34 | $171 |
| 82728 Clinical Chemistry | 17 | 14 | $13.36 | $227 |
| 84466 Clinical Chemistry | 15 | 12 | $12.50 | $188 |
| 83540 Clinical Chemistry | 15 | 12 | $6.34 | $95.1 |
| 80053 Clinical Chemistry | 14 | 11 | $10.35 | $145 |
| 82607 Clinical Chemistry | 14 | 13 | $14.78 | $207 |
| 82784 Immunoassay | 12 | 11 | $9.11 | $109 |
| 80076 Clinical Chemistry | 12 | 11 | $8.01 | $96.12 |
Medicare prescription drug claims, 2024
In 2024, the drug Michal F Tomczak prescribed most often to Medicare patients was Gavilyte-C (Peg3350/Sod Sulf,bicarb,cl/Kcl), with 150 prescriptions and refills. In total Michal F Tomczak wrote 888 Medicare prescriptions that cost $188K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 150 | 150 | 144 | $2,708 |
| Omeprazole Generic | 139 | 306 | 45 | $2,278 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 136 | 136 | 135 | $9,005 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-C Peg3350/Sod Sul/Nacl/Kcl/Asb/C | 131 | 131 | 125 | $9,085 |
| Pantoprazole Sodium Generic | 51 | 113 | 16 | $865 |
| Famotidine Generic | 25 | 44 | Under 11 | $206 |
| Budesonide Ec Budesonide | 23 | 33 | Under 11 | $6,299 |
| Creon Lipase/Protease/Amylase | 17 | 23 | Under 11 | $10K |
| Mesalamine Generic | 16 | 34 | Under 11 | $8,681 |
| Linzess Linaclotide | 13 | 25 | Under 11 | $13K |
| Xeljanz Tofacitinib Citrate | 13 | 13 | Under 11 | $66K |
| Ondansetron Hcl Generic | 13 | 13 | Under 11 | $32.49 |
| Esomeprazole Magnesium Generic | 12 | 28 | Under 11 | $457 |
| Dexilant Dexlansoprazole | 11 | 11 | Under 11 | $6,020 |
Brand drugs: 148 claims; generic drugs: 740 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Michal F Tomczak were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.